Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
This grant funds research and development of drugs for Alzheimer's disease.
About this program
The Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is designed to support innovative research aimed at developing new therapies for Alzheimer's disease. This program is intended for academic institutions, nonprofit organizations, and small businesses that are engaged in drug development. The grant provides funding to facilitate clinical trials and other research activities that can lead to effective treatments for Alzheimer's patients. Eligible applicants can utilize the funding to conduct preclinical and clinical studies, as well as to explore novel therapeutic approaches. The program encourages collaboration among researchers, healthcare providers, and industry partners to accelerate the drug development process. By fostering innovation and supporting promising research, this grant aims to make significant advancements in the fight against Alzheimer's disease.
Eligibility
Academic institutions, nonprofit organizations, and small businesses engaged in drug development.
Requirements
- Must focus on Alzheimer's disease
- Clinical trial optional